Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 5Breast 5Gastrointestinal 4Tumor-Agnostic 1Head & Neck 1Gynecologic 1Genitourinary 1Dermatologic 1

Conditions

Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Melanoma 1Lung Neoplasms 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 29Nivolumab 29Specimen Handling 24Ipilimumab 19Magnetic Resonance Spectroscopy 17Biopsy 11CTLA-4 Antigen 9Opdualag 8Cyclophosphamide 8relatlimab 6Paclitaxel 6trametinib 5fludarabine 5cemiplimab 5Carboplatin 5fludarabine phosphate 4dabrafenib 4binimetinib 4avelumab 4HhAntag691 4lifileucel 3capivasertib 3atezolizumab 3aldesleukin 3X-Rays 3Temozolomide 3Taxes 3Surgical Procedures, Operative 3Standard of Care 3Pemetrexed 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
patritumab deruxtecan × Dermatologic × 30 days × Clear all
NCT06172478 2026-05-15

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Daiichi Sankyo

Phase 2 Recruiting
740 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡